Adalimumab for sight-threatening uveitis in Behçet's disease

B Mushtaq; T Saeed; Rohan Situnayake; Philip Murray

doi:10.1038/sj.eye.6702352

Adalimumab for sight-threatening uveitis in Behçet's disease

B Mushtaq
, T Saeed
, Rohan Situnayake
, Philip Murray

Immunology and Immunotherapy

Research output: Contribution to journal › Article

137 Citations (Scopus)

Abstract

AIMS: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. METHODS: Case note review. Main outcome measure was recurrence of uveitis. RESULTS: All patients remained free of recurrence with stable visual acuities. CONCLUSIONS: Adalimumab appears to maintain disease remission in Behçet's disease.

Original language	English
Pages (from-to)	824-5
Number of pages	2
Journal	Eye
Volume	21
Issue number	6
Early online date	7 Apr 2006
DOIs	https://doi.org/10.1038/sj.eye.6702352
Publication status	Published - 7 Apr 2006

Access to Document

10.1038/sj.eye.6702352

Cite this

@article{e902505a63a448c7b95db4f8119da81b,

title = "Adalimumab for sight-threatening uveitis in Beh{\c c}et's disease",

abstract = "AIMS: To describe the clinical outcome of three patients with Beh{\c c}et's disease maintained on infliximab who were switched to adalimumab therapy. METHODS: Case note review. Main outcome measure was recurrence of uveitis. RESULTS: All patients remained free of recurrence with stable visual acuities. CONCLUSIONS: Adalimumab appears to maintain disease remission in Beh{\c c}et's disease.",

author = "B Mushtaq and T Saeed and Rohan Situnayake and Philip Murray",

year = "2006",

month = apr,

day = "7",

doi = "10.1038/sj.eye.6702352",

language = "English",

volume = "21",

pages = "824--5",

journal = "Eye",

issn = "1476-5454",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Adalimumab for sight-threatening uveitis in Behçet's disease

AU - Mushtaq, B

AU - Saeed, T

AU - Situnayake, Rohan

AU - Murray, Philip

PY - 2006/4/7

Y1 - 2006/4/7

N2 - AIMS: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. METHODS: Case note review. Main outcome measure was recurrence of uveitis. RESULTS: All patients remained free of recurrence with stable visual acuities. CONCLUSIONS: Adalimumab appears to maintain disease remission in Behçet's disease.

AB - AIMS: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. METHODS: Case note review. Main outcome measure was recurrence of uveitis. RESULTS: All patients remained free of recurrence with stable visual acuities. CONCLUSIONS: Adalimumab appears to maintain disease remission in Behçet's disease.

U2 - 10.1038/sj.eye.6702352

DO - 10.1038/sj.eye.6702352

M3 - Article

C2 - 16601736

SN - 1476-5454

VL - 21

SP - 824

EP - 825

JO - Eye

JF - Eye

IS - 6

ER -

Adalimumab for sight-threatening uveitis in Behçet's disease

Abstract

Access to Document

Fingerprint

Cite this